Stay updated on Johnson & Johnson Press Releases
Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FiC4AwYb6fnE_sh78Yw3HKfBIhGY.uncropped.jpg&w=3840&q=75)
Latest updates to the Johnson & Johnson Press Releases page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoChange DetectedThe website now shows an increase to 1,974 results, highlighting Johnson & Johnson's upcoming participation in the Morgan Stanley Global Healthcare Conference on July 23, 2024, while the previous entry about their Sight For Kids program has been removed.SummaryDifference11%
- Check4 days agoChange DetectedThe website has added content on Innovative Medicine while removing references to Pharmaceuticals.SummaryDifference0.4%
- Check5 days agoChange DetectedJohnson & Johnson has updated its results to 1,973 and is seeking FDA approval for SPRAVATO® as a monotherapy for treatment-resistant depression, highlighting rapid symptom improvement and extensive research backing its efficacy.SummaryDifference14%
- Check6 days agoChange DetectedThe website has added new features, while the option to customize cookie settings has been removed.SummaryDifference0.4%
- Check7 days agoChange DetectedThe website has introduced a new feature allowing users to customize their cookie settings.SummaryDifference0.4%
- Check9 days agoChange DetectedThe website has added updates on the company's Q2 2024 results, including sales growth, earnings per share, new product pipeline progress, and guidance adjustments for the full year 2024. Additionally, CARVYKTI® achieved statistically significant improvement, indicating positive developments for the company.SummaryDifference100%
Stay in the know with updates to Johnson & Johnson Press Releases
Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.